Regulatory News:
Cellectis stem cells, a Business Unit of Cellectis Group
(Alternext: ALCLS), a premier provider of stem cell derived products and
technologies, today announces the launch of a human iPS derived
hepatocyte product, hiPS-HEPTM.
The hiPS-HEPTM demonstrate high reproducibility, homogeneity
and a long life span of stable CYP activity, making them the ideal
platform for various in vitro applications including drug
discovery, toxicity testing and vaccine development. The hiPS-HEP™ are
human hepatocyte-like cells derived from human induced Pluripotent Stem
(iPS) cells under strict quality controlled and ethically approved
procedures.
"Due to their high relevance in various industrial applications it makes
the hiPS-HEP™ a really promising system for research and development,"
said Johan Hyllner, CSO of Cellectis stem cells. "The pharmaceutical
industry has a great need for better and more clinically relevant models
early in the drug development process to predict hepatotoxicity, find
new drug targets and develop new vaccines."
"This novel product is the fruition of Cellectis’ strategy to become the
global market leader for stem cell-based in vitro models and
related technologies. It illustrates our ambitions and the momentum of
our future development in this field," said André Choulika, Chairman and
CEO of Cellectis.
About Cellectis stem cells:
Cellectis stem cells, is a business unit within the Cellectis group and
is a global leader in stem cell technology. Cellectis stem cells,
created in November 2011 from Cellartis AB and Ectycell SAS, possesses
broad expertise in pluripotent stem cells, including iPS cell
technology, genetic engineering and specialised cells. Cellectis stem
cells is developing stem cell derived products and related services for
drug discovery, toxicity testing and regenerative medicine applications.
For more information visit www.cellartis.com
and www.cellectis.com
About Cellectis
Cellectis improves life by applying its genome engineering expertise to
a broad range of applications, including human therapeutics, biological
research and agriculture. Cellectis is listed on the NYSE-Euronext Paris
Alternext market (code: ALCLS).
To find out more, visit www.cellectis.com.
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
